Personalized Healthcare and Your Data: A New Era in Medicine

4:00 PM - 4:45 PM (EDT), Wednesday, June 16, 2021
Search General Info
Search Education
Search Partnering Companies

For over a decade now, the patient’s journey through the healthcare system has been evolving to help realize the vision of personalized medicine—to deliver the right treatment for the right patient at the right time. Molecular testing provides patient health data that can be utilized to aid in treatment management decisions, yielding both clinical utility for patients and economic value for the health system. 

Indeed, personalized medicine tests and treatments are rapidly coming to market. Over 25% of newly approved drugs over the last six years have been targeted therapeutics, and it is estimated that there are now over 60,000 commercially available diagnostic tests. Many molecular testing technologies, however, are relatively new and therefore underutilized. For example, a study by LUNGevity found that low rates of biomarker testing is especially pronounced in underserved communities – patients on Medicaid are 40% less likely to get tested than those with private health insurance; and Medicaid patients are 30% less likely than patients who are privately insured to receive targeted therapies following testing. Thus, the clinical adoption of personalized medicine requires a comprehensive and adaptable approach from all stakeholders to more effectively integrate innovative solutions and patient data to improve patient outcomes and reduce disparities.

This session will feature a discussion on what is necessary for the successful implementation of personalized medicine strategies. They will highlight challenges and solutions related to education and awareness, barriers to access, clinical practices, and data management, with a focus on solutions for overcoming these challenges.